A recent study has revealed the interaction of PKCε with Akt, suggesting that the downregulation of PKCε causes the inhibition of Akt in breast cancer cells, thus increasing drug efficacy in breast cancer patients (22). This evidence concerns the gene AKT1 and breast cancer.